Inlyta
- Generic Name: axitinib
- Brand Name: Inlyta
- Drug Class: Antineoplastics, VEGF Inhibitor, Antineoplastic Tyrosine Kinase Inhibitors
Inlyta (Axitinib) side effects drug center
- Related Drugs
- Health Resources
- diarrhea,
- high blood pressure (hypertension),
- fatigue, decreased appetite,
- nausea,
- loss of voice,
- hand-foot syndrome (palmar-plantar erythrodysesthesia),
- weight loss,
- vomiting,
- weakness, and
- constipation
- chest pain or pressure, pain spreading to your jaw or shoulder, trouble breathing;
- sudden numbness or weakness, problems with vision or speech;
- headache, confusion, thinking problems, seizure (convulsions);
- a light-headed feeling, like you might pass out;
- easy bruising, unusual bleeding, purple or red spots under your skin;
- heavy menstrual bleeding;
- any bleeding that will not stop;
- pink or brown urine;
- heart problems--swelling, rapid weight gain, feeling short of breath;
- signs of stomach bleeding--bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds; or
- signs of a thyroid problem--sudden weight gain or loss, feeling very weak or tired, muscle pain, feeling hot or cold, hair loss, hoarse or deepened voice.
- nausea, vomiting, diarrhea, constipation;
- rash, itching, redness, and peeling skin on your hands or feet;
- feeling weak or tired;
- increased blood pressure;
- decreased appetite, weight loss; or
- hoarse voice.
- Hypertension and hypertensive crisis [see WARNINGS AND PRECAUTIONS]
- Arterial thromboembolic events [see WARNINGS AND PRECAUTIONS]
- Venous thromboembolic events [see WARNINGS AND PRECAUTIONS]
- Hemorrhage [see WARNINGS AND PRECAUTIONS]
- Cardiac failure [see WARNINGS AND PRECAUTIONS]
- Gastrointestinal perforation and fistula formation [see WARNINGS AND PRECAUTIONS]
- Thyroid dysfunction [see WARNINGS AND PRECAUTIONS]
- Reversible posterior leukoencephalopathy syndrome [see WARNINGS AND PRECAUTIONS]
- Proteinuria [see WARNINGS AND PRECAUTIONS]
- Hepatotoxicity [see WARNINGS AND PRECAUTIONS]
- Hepatic impairment [see WARNINGS AND PRECAUTIONS]
What Is Inlyta?
Inlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy for this type of cancer.
What Are Side Effects of Inlyta?
Common side effects of Inlyta include:
Dosage for Inlyta
Inlyta comes in 1 mg and 5 mg strengths. The starting dose is 5 mg taken orally twice daily, approximately 12 hours, with a full glass or water, with or without food.
What Drugs, Substances, or Supplements Interact with Inlyta?
Inlyta may interact with boceprevir, bosentan, conivaptan, dexamethasone, imatinib, isoniazid, nefazodone, St. John's wort, theophylline, antibiotics, antifungal medications, barbiturates, heart or blood pressure medications, HIV/AIDS medications, medicines to treat narcolepsy, or seizure medications. Tell your doctor all medications and supplements you use.
Inlyta During Pregnancy and Breastfeeding
Inlyta can be harmful to unborn children causing severe birth defects or death. Women who can become pregnant should evaluate the risks of using Erivedge with their doctors. It is not known if Inlyta passes into breast milk. The patient and the doctor should decide whether or not to take Inlyta. Nursing mothers should not do both.
Additional Information
Our Inlyta Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some people taking axitinib have developed a perforation (a hole or tear) or a fistula (an abnormal passageway) within the stomach or intestines. Call your doctor if you have severe stomach pain, or if you feel like you are choking and gagging when you eat or drink.
Also call your doctor at once if you have:
Common side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Inlyta (Axitinib)
SIDE EFFECTS
The following clinically significant adverse reactions are discussed elsewhere in the labeling [see WARNINGS AND PRECAUTIONS]:
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of INLYTA has been evaluated in combination with avelumab in JAVELIN Renal 101 and pembrolizumab in KEYNOTE-426 for the first-line treatment of patients with advanced RCC [see Clinical Studies]. The data described [see ADVERSE REACTIONS] reflect exposure to INLYTA in combination with avelumab in 434 patients and pembrolizumab in 429 patients [see Clinical Studies].
The safety of INLYTA has been evaluated in 715 patients in second-line monotherapy studies, which included 537 patients with advanced RCC. The data described [see ADVERSE REACTIONS] reflect exposure to INLYTA in 359 patients with advanced RCC who participated in a randomized clinical study versus sorafenib [see Clinical Studies].
First-Line Advanced RCC
INLYTA In Combination With Avelumab
The safety of INLYTA in combination with avelumab was evaluated in JAVELIN Renal 101. Patients with autoimmune disease other than type I diabetes mellitus, vitiligo, psoriasis, or thyroid disorders not requiring immunosuppressive treatment were excluded. Patients received INLYTA 5 mg twice daily (N=434) in combination with avelumab 10 mg/kg every 2 weeks administered or sunitinib 50 mg once daily for 4 weeks followed by 2 weeks off (N=439).
In the INLYTA plus avelumab arm, 70% were exposed to avelumab for ≥6 months and 29% were exposed for ≥1 year in JAVELIN Renal 101 [see Clinical Studies].
The median age of patients treated with INLYTA in combination with avelumab was 62 years (range: 29 to 83), 38% of patients were 65 years or older, 71% were male, 75% were White, and the Eastern Cooperative Oncology Group (ECOG) performance score was 0 (64%) or 1 (36%).
Fatal adverse reactions occurred in 1.8% of patients receiving INLYTA in combination with avelumab. These included sudden cardiac death (1.2%), stroke (0.2%), myocarditis (0.2%), and necrotizing pancreatitis (0.2%).
Serious adverse reactions occurred in 35% of patients receiving INLYTA in combination with avelumab. Serious adverse reactions in ≥1% of patients included diarrhea (2.5%), dyspnea (1.8%), hepatotoxicity (1.8%), venous thromboembolic disease (1.6%), acute kidney injury (1.4%), and pneumonia (1.2%).
Permanent discontinuation due to an adverse reaction of either INLYTA or avelumab occurred in 22% of patients: 19% avelumab only, 13% INLYTA only, and 8% both drugs. The most common adverse reactions (>1%) resulting in permanent discontinuation of avelumab or the combination were hepatotoxicity (6%) and infusion-related reaction (1.8%).
Dose interruptions or reductions due to an adverse reaction, excluding temporary interruptions of avelumab infusions due to infusion-related reactions, occurred in 76% of patients receiving INLYTA in combination with avelumab. This includes interruption of avelumab in 50% of patients. INLYTA was interrupted in 66% and dose reduced in 19% of patients. The most common adverse reaction (>10%) resulting in interruption of avelumab was diarrhea (10%) and the most common adverse reactions resulting in either interruption or dose reduction of INLYTA were diarrhea (19%), hypertension (18%), palmar-plantar erythrodysesthesia (18%), and hepatotoxicity (10%).
The most common adverse reactions (≥20%) in patients receiving INLYTA in combination with avelumab were diarrhea, fatigue, hypertension, musculoskeletal pain, nausea, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, abdominal pain, and headache.
Forty-eight (11%) of patients treated with INLYTA in combination with avelumab received an oral prednisone dose equivalent to ≥40 mg daily for an immune-mediated adverse reaction [see WARNINGS AND PRECAUTIONS].
Table 1 summarizes adverse reactions that occurred in ≥20% of INLYTA in combination with avelumab-treated patients.
Table 1: Adverse Reactions (≥20%) of Patients Receiving INLYTA in Combination with Avelumab (JAVELIN Renal 101 Trial)1
| Adverse Reactions | INLYTA plus Avelumab (N=434) | Sunitinib (N=439) | ||
| All Grades % | Grade 3-4 % | All Grades % | Grade 3-4 % | |
| Gastrointestinal Disorders | ||||
| Diarrhea2 | 62 | 8 | 48 | 2.7 |
| Nausea | 34 | 1.4 | 39 | 1.6 |
| Mucositis3 | 34 | 2.8 | 35 | 2.1 |
| Hepatotoxicity4 | 24 | 9 | 18 | 3.6 |
| Abdominal pain5 | 22 | 1.4 | 19 | 2.1 |
| General Disorders and Administration Site Conditions | ||||
| Fatigue6 | 53 | 6 | 54 | 6 |
| Vascular Disorders | ||||
| Hypertension7 | 50 | 26 | 36 | 17 |
| Musculoskeletal and Connective Tissue Disorders | ||||
| Musculoskeletal pain8 | 40 | 3.2 | 33 | 2.7 |
| Skin and Subcutaneous Tissue Disorders | ||||
| Palmar-plantar erythrodysesthesia | 33 | 6 | 34 | 4 |
| Rash9 | 25 | 0.9 | 16 | 0.5 |
| Respiratory, Thoracic and Mediastinal Disorders | ||||
| Dysphonia | 31 | 0.5 | 3.2 | 0 |
| Dyspnea10 | 23 | 3.0 | 16 | 1.8 |
| Cough | 23 | 0.2 | 19 | 0 |
| Metabolism and Nutrition Disorders | ||||
| Decreased appetite | 26 | 2.1 | 29 | 0.9 |
| Endocrine Disorders | ||||
| Hypothyroidism | 25 | 0.2 | 14 | 0.2 |
| Nervous System Disorders | ||||
| Headache | 21 | 0.2 | 16 | 0.2 |
| Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events. Version 4.03 (NCI CTCAE v4). 1 The trial was not designed to demonstrate a statistically significant difference in the incidence of adverse reactions between avelumab in combination with INLYTA and sunitinib. 2 Diarrhea is a composite term that includes diarrhea, autoimmune colitis, and colitis 3 Mucositis is a composite term that includes mucosal inflammation and stomatitis 4 Hepatotoxicity is a composite term that includes ALT increased, AST increased, autoimmune hepatitis, bilirubin conjugated, bilirubin conjugated increased, blood bilirubin increased, drug-induced liver injury, hepatic enzyme increased, hepatic function abnormal, hepatitis, hepatitis fulminant, hepatocellular injury, hepatotoxicity, hyperbilirubinemia, immune-mediated hepatitis, liver function test increased, liver disorder, liver injury, and transaminases increased 5 Abdominal pain is a composite term that includes abdominal pain, flank pain, abdominal pain upper, and abdominal pain lower 6 Fatigue is a composite term that includes fatigue and asthenia 7 Hypertension is a composite term that includes hypertension and hypertensive crisis 8 Musculoskeletal pain is a composite term that includes musculoskeletal pain, musculoskeletal chest pain, myalgia, back pain, bone pain, musculoskeletal discomfort, neck pain, spinal pain, and pain in extremity 9 Rash is a composite term that includes rash, rash generalized, rash macular, rash maculo-papular, rash pruritic, rash erythematous, rash papular, and rash pustular 10 Dyspnea is a composite term that includes dyspnea, dyspnea exertional and dyspnea at rest | ||||
Other clinically important adverse reactions that occurred in less than 20% of patients in JAVELIN Renal 101 included arthralgia, weight decreased, and chills.
Patients received pre-medication with an anti-histamine and acetaminophen prior to each infusion. Infusion-related reactions occurred in 12% (Grade 3: 1.6%; no Grade 4) of patients treated with INLYTA in combination with avelumab.
Table 2 summarizes selected laboratory abnormalities that occurred in ≥20% of INLYTA in combination with avelumab-treated patients.
Table 2: Selected Laboratory Abnormalities Worsening from Baseline Occurring in ≥20% of Patients Receiving INLYTA in Combination with Avelumab (JAVELIN Renal 101 Trial)1
| Laboratory Abnormality | INLYTA plus Avelumab | Sunitinib2 | ||
| Any Grade % | Grade 3-4 % | Any Grade % | Grade 3-4 % | |
| Chemistry | ||||
| Blood triglycerides increased | 71 | 13 | 48 | 5 |
| Blood creatinine increased | 62 | 2.3 | 68 | 1.4 |
| Blood cholesterol increased | 57 | 1.9 | 22 | 0.7 |
| Alanine aminotransferase increased (ALT) | 50 | 9 | 46 | 3.2 |
| Aspartate aminotransferase increased (AST) | 47 | 7 | 57 | 3.2 |
| Blood sodium decreased | 38 | 9 | 37 | 10 |
| Lipase increased | 37 | 14 | 25 | 7 |
| Blood potassium increased | 35 | 3.0 | 28 | 3.9 |
| Blood bilirubin increased | 21 | 1.4 | 23 | 1.4 |
| Hematology | ||||
| Platelet count decreased | 27 | 0.7 | 80 | 1.5 |
| Hemoglobin decreased | 21 | 2.1 | 65 | 8 |
| 1 The trial was not designed to demonstrate a statistically significant difference in the incidence of laboratory abnormalities between INLYTA in combination with avelumab and sunitinib. 2 Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: INLYTA in combination with avelumab group (range: 413 to 428 patients) and sunitinib group (range: 405 to 433 patients). | ||||
INLYTA In Combination With Pembrolizumab
The safety of INLYTA in combination with pembrolizumab was investigated in KEYNOTE-426 [see Clinical Studies]. Patients with medical conditions that required systemic corticosteroids or other immunosuppressive medications or had a history of severe autoimmune disease other than type 1 diabetes, vitiligo, Sjogren's syndrome, and hypothyroidism stable on hormone replacement were ineligible. Patients received INLYTA 5 mg orally twice daily and pembrolizumab 200 mg intravenously every 3 weeks, or sunitinib 50 mg once daily for 4 weeks and then off treatment for 2 weeks. The median duration of exposure to the combination therapy of INLYTA and pembrolizumab was 10.4 months (range: 1 day to 21.2 months).
The study population characteristics were: median age of 62 years (range: 30 to 89), 40% age 65 or older; 71% male; 80% White; and 80% Karnofsky Performance Status (KPS) of 90-100 and 20% KPS of 70-80.
Fatal adverse reactions occurred in 3.3% of patients receiving INLYTA in combination with pembrolizumab. These included 3 cases of cardiac arrest, 2 cases of pulmonary embolism and 1 case each of cardiac failure, death due to unknown cause, myasthenia gravis, myocarditis, Fournier's gangrene, plasma cell myeloma, pleural effusion, pneumonitis, and respiratory failure.
Serious adverse reactions occurred in 40% of patients receiving INLYTA in combination with pembrolizumab. Serious adverse reactions in ≥1% of patients receiving INLYTA in combination with pembrolizumab included hepatotoxicity (7%), diarrhea (4.2%), acute kidney injury (2.3%), dehydration (1%), and pneumonitis (1%).
Permanent discontinuation due to an adverse reaction of either INLYTA or pembrolizumab occurred in 31% of patients; 13% pembrolizumab only, 13% INLYTA only, and 8% both drugs. The most common adverse reaction (>1%) resulting in permanent discontinuation of INLYTA, pembrolizumab, or the combination was hepatotoxicity (13%), diarrhea/colitis (1.9%), acute kidney injury (1.6%), and cerebrovascular accident (1.2%).
Dose interruptions or reductions due to an adverse reaction, excluding temporary interruptions of pembrolizumab infusions due to infusion-related reactions, occurred in 76% of patients receiving pembrolizumab in combination with axitinib. This includes interruption of pembrolizumab in 50% of patients. INLYTA was interrupted in 64% of patients and dose reduced in 22% of patients. The most common adverse reactions (>10%) resulting in either interruption or reduction of INLYTA were hepatotoxicity (21%), diarrhea (19%), and hypertension (18%) and the most common adverse reactions (>10%) resulting in interruption of pembrolizumab were hepatotoxicity (14%) and diarrhea (11%).
The most common adverse reactions (≥20%) in patients receiving INLYTA and pembrolizumab were diarrhea, fatigue/asthenia, hypertension, hypothyroidism, decreased appetite, hepatotoxicity, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.
Twenty-seven percent (27%) of patients treated with INLYTA in combination with pembrolizumab received an oral prednisone dose equivalent to ≥40 mg daily for an immune-mediated adverse reaction.
Tables 3 and 4 summarize the adverse reactions and laboratory abnormalities, respectively, that occurred in at least 20% of patients treated with INLYTA and pembrolizumab in KEYNOTE-426.
Table 3: Adverse Reactions Occurring in ≥20% of Patients Treated with INLYTA and Pembrolizumab (KEYNOTE-426 Trial)
| Adverse Reactions | INLYTA plus Pembrolizumab N=429 | Sunitinib N=425 | ||
| All Grades* % | Grades 3-4 % | All Grades % | Grades 3-4 % | |
| Gastrointestinal Disorders | ||||
| Diarrhea† | 56 | 11 | 45 | 5 |
| Nausea | 28 | 0.9 | 32 | 0.9 |
| Constipation | 21 | 0 | 15 | 0.2 |
| General | ||||
| Fatigue/Asthenia | 52 | 5 | 51 | 10 |
| Vascular | ||||
| Hypertension‡ | 48 | 24 | 48 | 20 |
| Hepatobiliary | ||||
| Hepatotoxicity§ | 39 | 20 | 25 | 4.9 |
| Endocrine | ||||
| Hypothyroidism | 35 | 0.2 | 32 | 0.2 |
| Metabolism and Nutrition | ||||
| Decreased appetite | 30 | 2.8 | 29 | 0.7 |
| Skin and Subcutaneous Tissue | ||||
| Palmar-plantar erythrodysesthesia syndrome | 28 | 5 | 40 | 3.8 |
| Stomatitis/Mucosal inflammation | 27 | 1.6 | 41 | 4 |
| Rash¶ | 25 | 1.4 | 21 | 0.7 |
| Respiratory, Thoracic, and Mediastinal | ||||
| Dysphonia | 25 | 0.2 | 3.3 | 0 |
| Cough | 21 | 0.2 | 14 | 0.5 |
| * Graded per NCI CTCAE v4.03 † Includes diarrhea, colitis, enterocolitis, gastroenteritis, enteritis, enterocolitis hemorrhagic ‡ Includes hypertension, blood pressure increased, hypertensive crisis, labile hypertension § Includes ALT increased, AST increased, autoimmune hepatitis, blood bilirubin increased, drug-induced liver injury, hepatic enzyme increased, hepatic function abnormal, hepatitis, hepatitis fulminant, hepatocellular injury, hepatotoxicity, hyperbilirubinemia, immune-mediated hepatitis, liver function test increased, liver injury, transaminases increased ¶ Includes rash, butterfly rash, dermatitis, dermatitis acneform, dermatitis atopic, dermatitis, bullous, dermatitis contact, exfoliative rash, genital rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, seborrheic dermatitis, skin discoloration, skin exfoliation, perineal rash | ||||
Table 4: Laboratory Abnormalities Worsened from Baseline Occurring in ≥20% of Patients Receiving INLYTA With Pembrolizumab in KEYNOTE-426
| Laboratory Test* | INLYTA plus Pembrolizumab | Sunitinib | ||
| All Grades† % | Grade 3-4 % | All Grades % | Grade 3-4 % | |
| Chemistry | ||||
| Hyperglycemia | 62 | 9 | 54 | 3.2 |
| Increased ALT | 60 | 20 | 44 | 5 |
| Increased AST | 57 | 13 | 56 | 5 |
| Increased creatinine | 43 | 4.3 | 40 | 2.4 |
| Hyponatremia | 35 | 8 | 29 | 8 |
| Hyperkalemia | 34 | 6 | 22 | 1.7 |
| Hypoalbuminemia | 32 | 0.5 | 34 | 1.7 |
| Hypercalcemia | 27 | 0.7 | 15 | 1.9 |
| Hypophosphatemia | 26 | 6 | 49 | 17 |
| Increased alkaline phosphatase | 26 | 1.7 | 30 | 2.7 |
| Hypocalcemia‡ | 22 | 0.2 | 29 | 0.7 |
| Blood bilirubin increased | 22 | 2.1 | 21 | 1.9 |
| Activated partial thromboplastin time prolonged§ | 22 | 1.2 | 14 | 0 |
| Hematology | ||||
| Lymphopenia | 33 | 11 | 46 | 8 |
| Anemia | 29 | 2.1 | 65 | 8 |
| Thrombocytopenia | 27 | 1.4 | 78 | 14 |
| * Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: pembrolizumab/axitinib (range: 342 to 425 patients) and sunitinib (range: 345 to 422 patients). † Graded per NCI CTCAE v4.03 ‡ Corrected for albumin § Two patients with a Grade 3 elevated activated partial thromboplastin time prolonged (aPTT) were also reported as having an adverse reaction of hepatotoxicity. | ||||
Second-Line Advanced RCC
The median duration of treatment was 6.4 months (range 0.03 to 22.0) for patients who received INLYTA and 5.0 months (range 0.03 to 20.1) for patients who received sorafenib. Dose modifications or temporary delay of treatment due to an adverse reaction occurred in 199/359 patients (55%) receiving INLYTA and 220/355 patients (62%) receiving sorafenib. Permanent discontinuation due to an adverse reaction occurred in 34/359 patients (9%) receiving INLYTA and 46/355 patients (13%) receiving sorafenib.
The most common (≥20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation. Table 5 presents adverse reactions reported in ≥10% patients who received INLYTA or sorafenib.
Table 5: Adverse Reactions Occurring in ≥10% of Patients Who Received INLYTA or Sorafenib
| Adverse Reactiona | INLYTA (N=359) | Sorafenib (N=355) | ||
| All Gradesb% | Grade 3/4 % | All Gradesb% | Grade 3/4 % | |
| Diarrhea | 55 | 11 | 53 | 7 |
| Hypertension | 40 | 16 | 29 | 11 |
| Fatigue | 39 | 11 | 32 | 5 |
| Decreased appetite | 34 | 5 | 29 | 4 |
| Nausea | 32 | 3 | 22 | 1 |
| Dysphonia | 31 | 0 | 14 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | 27 | 5 | 51 | 16 |
| Weight decreased | 25 | 2 | 21 | 1 |
| Vomiting | 24 | 3 | 17 | 1 |
| Asthenia | 21 | 5 | 14 | 3 |
| Constipation | 20 | 1 | 20 | 1 |
| Hypothyroidism | 19 | <1 | 8 | 0 |
| Cough | 15 | 1 | 17 | 1 |
| Mucosal inflammation | 15 | 1 | 12 | 1 |
| Arthralgia | 15 | 2 | 11 | 1 |
| Stomatitis | 15 | 1 | 12 | <1 |
| Dyspnea | 15 | 3 | 12 | 3 |
| Abdominal pain | 14 | 2 | 11 | 1 |
| Headache | 14 | 1 | 11 | 0 |
| Pain in extremity | 13 | 1 | 14 | 1 |
| Rash | 13 | <1 | 32 | 4 |
| Proteinuria | 11 | 3 | 7 | 2 |
| Dysgeusia | 11 | 0 | 8 | 0 |
| Dry skin | 10 | 0 | 11 | 0 |
| Dyspepsia | 10 | 0 | 2 | 0 |
| Pruritus | 7 | 0 | 12 | 0 |
| Alopecia | 4 | 0 | 32 | 0 |
| Erythema | 2 | 0 | 10 | <1 |
| a Percentages are treatment-emergent, all-causality events b National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 | ||||
Selected adverse reactions (all grades) that were reported in <10% of patients treated with INLYTA included dizziness (9%), upper abdominal pain (8%), myalgia (7%), dehydration (6%), epistaxis (6%), anemia (4%), hemorrhoids (4%), hematuria (3%), tinnitus (3%), lipase increased (3%), glossodynia (3%), pulmonary embolism (2%), rectal hemorrhage (2%), hemoptysis (2%), deep vein thrombosis (1%), retinal-vein occlusion/thrombosis (1%), polycythemia (1%), and transient ischemic attack (1%).
Table 6 presents the most common laboratory abnormalities reported in ≥10% patients who received INLYTA or sorafenib.
Table 6: Laboratory Abnormalities Occurring in ≥10% of Patients Who Received INLYTA or Sorafenib
| Laboratory Abnormality | N | INLYTA | N | Sorafenib | ||
| All Gradesa % | Grade 3/4 % | All Gradesa % | Grade 3/4 % | |||
| Hematology | ||||||
| Hemoglobin decreased | 320 | 35 | <1 | 316 | 52 | 4 |
| Lymphocytes (absolute) decreased | 317 | 33 | 3 | 309 | 36 | 4 |
| Platelets decreased | 312 | 15 | <1 | 310 | 14 | 0 |
| White blood cells decreased | 320 | 11 | 0 | 315 | 16 | <1 |
| Chemistry | ||||||
| Creatinine increased | 336 | 55 | 0 | 318 | 41 | <1 |
| Bicarbonate decreased | 314 | 44 | <1 | 291 | 43 | 0 |
| Hypocalcemia | 336 | 39 | 1 | 319 | 59 | 2 |
| ALP increased | 336 | 30 | 1 | 319 | 34 | 1 |
| Hyperglycemia | 336 | 28 | 2 | 319 | 23 | 2 |
| Lipase increased | 338 | 27 | 5 | 319 | 46 | 15 |
| Amylase increased | 338 | 25 | 2 | 319 | 33 | 2 |
| ALT increased | 331 | 22 | <1 | 313 | 22 | 2 |
| AST increased | 331 | 20 | <1 | 311 | 25 | 1 |
| Hypernatremia | 338 | 17 | 1 | 319 | 13 | 1 |
| Hypoalbuminemia | 337 | 15 | <1 | 319 | 18 | 1 |
| Hyperkalemia | 333 | 15 | 3 | 314 | 10 | 3 |
| Hypoglycemia | 336 | 11 | <1 | 319 | 8 | <1 |
| Hyponatremia | 338 | 13 | 4 | 319 | 11 | 2 |
| Hypophosphatemia | 336 | 13 | 2 | 318 | 49 | 16 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase | ||||||
Selected laboratory abnormalities (all grades) that were reported in <10% of patients treated with INLYTA included hemoglobin increased (above the upper limit of normal) (9% for INLYTA versus 1% for sorafenib) and hypercalcemia (6% for INLYTA versus 2% for sorafenib).
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of INLYTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Vascular disorders: arterial (including aortic) aneurysms, dissections, and rupture.
Read the entire FDA prescribing information for Inlyta (Axitinib)
© Inlyta Patient Information is supplied by Cerner Multum, Inc. and Inlyta Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.